Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study

References

• Tesfaye DY, Kinde S, Medhin G, et al. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia. Diabetes Metab Syndr. 2014;8(2):1–11. doi: 10.1016/j.dsx.2014.04.008.
   PubMedGoogle Scholar
• Altizani G, de Oliveira L, Dos Santos Tortajada J, et al. Management of cardiovascular and metabolic alterations in HIV positive patients. Int J AIDS Res. 2016;3(7):105–113.
   Google Scholar
• Dybul M, Attoye T, Baptiste S, et al. The case for an HIV cure and how to get there. Lancet HIV. 2021;8(1):e51–e8. doi: 10.1016/S2352-3018(20)30232-0.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization; 2021.
   Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization; 2016. Available from: https://www.afro.who.int/publications/national-consolidated-guidelines-comprehensive-hiv-prevention-care-and-treatment
   Google Scholar
• FMOH Ethiopia. National consolidated guidelines for comprehensive HIV prevention, care and treatment. Addis Ababa: FMOH Ethiopia; 2018.
   Google Scholar
• World Health Organization. Policy brief: update of recommendations on first- and second-line antiretroviral regimens. Geneva: World Health Organization; 2019 (Report No.: contract No.: WHO/CDS/HIV/19.15).
   Google Scholar
• World Health Organization. Policy brief: update of recommendations on first-and second-line antiretroviral regimens. World Health Organization; 2019.
   Google Scholar
• Shah BM, Schafer JJ, Desimone JA. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy. 2014;34(5):506–520. doi: 10.1002/phar.1386.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2020 abridged for primary care providers. Clin Diabetes. 2020;38(1):10–38. doi: 10.2337/cd20-as01.
   PubMedGoogle Scholar
• Thet D, Siritientong T. Antiretroviral therapy-associated metabolic complications: review of the recent studies. HIV AIDS. 2020;12:507–524. doi: 10.2147/hiv.s275314.
   Google Scholar
• Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743. doi: 10.1016/S0140-6736(12)61853-4.
   PubMed Web of Science ®Google Scholar
• Healthcare V. Tivicay (dolutegravir tablets). Full prescribing information. Research Triangle Park, NC: ViiV Healthcare.
   Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818. doi: 10.1056/NEJMoa1215541.
   PubMed Web of Science ®Google Scholar
• Calvo M, Martinez E. Update on metabolic issues in HIV patients. Curr Opin HIV AIDS. 2014;9(4):332–339. doi: 10.1097/coh.0000000000000075.
   PubMed Web of Science ®Google Scholar
• Singh J, Verma M, Ghalaut PS, et al. Alteration in lipid profile in treatment-naive HIV-infected patients and changes following HAART initiation in Haryana. J Endocrinol Metab. 2014;4:(1-2):25–31. doi: 10.14740/jem207w.
   Google Scholar
• Crocker MK, Yanovski JA. Pediatric obesity: etiology and treatment. Endocrinol Metab Clin North Am. 2009;38(3):525–548. doi: 10.1016/j.ecl.2009.06.007.
   Google Scholar
• Bjornstad P, Eckel RH. Pathogenesis of lipid disorders in insulin resistance: a brief review. Curr Diab Rep. 2018;18(12):127. doi: 10.1007/s11892-018-1101-6.
   PubMed Web of Science ®Google Scholar
• Taramasso L, Tatarelli P, Ricci E, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018;18(1):357. doi: 10.1186/s12879-018-3268-5.
   PubMedGoogle Scholar
• Bagella P, Squillace N, Ricci E, et al. Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project. Infect Drug Resist. 2019;12:1385–1391. doi: 10.2147/idr.s203813.
   PubMed Web of Science ®Google Scholar
• Hamooya BM, Musonda P, Mutale W, et al. Prevalence of low high-density lipoprotein among young adults receiving antiretroviral therapy in Zambia: an opportunity to consider non-communicable diseases in resource-limited settings. PLOS One. 2021;16(2):e0247004. doi: 10.1371/journal.pone.0247004.
   PubMed Web of Science ®Google Scholar
• Tadewos A, Addis Z, Ambachew H, et al. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther. 2012;9(1):31. doi: 10.1186/1742-6405-9-31.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–3421.
   PubMed Web of Science ®Google Scholar
• Services UDoHaH. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events National Institute of Allergy and Infectious Diseases: National Institutes of Health; Corrected Version 2.1; July 2017 [cited 2021 Oct 10]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.
   Google Scholar
• World Health Organization. Technical package for cardiovascular disease management in primary health care: evidence-based treatment protocols. Geneva: World Health Organization; 2018. (Report No.: contract No.: WHO/NMH/NVI/18.2).
   Google Scholar
• WHO Consultation on Obesity. Obesity: preventing and managing the global epidemic: report of a WHO consultation. Geneva: World Health Organization; 2000.
   Google Scholar
• World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8–11 December 2008; 2011. Available from: http://www.who.int/entity/nutrition/publications/obesity/WHO_report_waistcircumference_and_ waisthip_ratio/en/
   Google Scholar
• Riley L, Guthold R, Cowan M, et al. The World Health Organization STEPwise Approach to Noncommunicable Disease Risk-Factor Surveillance: Methods, Challenges, and Opportunities. Am J Public Health. 2016;106(1):74–78. doi:10.2105/AJPH.2015.3029627.
   Google Scholar
• Bull FC, Al-Ansari SS, Biddle S, et al. World health ­organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451–1462. doi: 10.1136/bjsports-2020-102955.
   PubMed Web of Science ®Google Scholar
• Hannon BA, Khan NA, Teran-Garcia M. Nutrigenetic contributions to dyslipidemia: a focus on physiologically relevant pathways of lipid and lipoprotein metabolism. Nutrients. 2018;10(10):1404. doi: 10.3390/nu10101404.
   PubMed Web of Science ®Google Scholar
• Gelibo T, Amenu K, Taddele T, et al. Low fruit and vegetable intake and its associated factors in Ethiopia: a community based cross sectional NCD steps survey. Ethiopian J Health Develop. 2017;31(1):355–361.
   Web of Science ®Google Scholar
• Hosner DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Son; 1989. p. 581.
   Google Scholar
• Kouanfack C, Kuate L, Zemsi S, et al. Clinical, biochemical and CT-scan characteristics of obesity onset in patients under dolutegravir in comparison with low-dose-efavirenz: a pilot study in Cameroon. Health Sci dis. 2021;22(3):1–8.
   Google Scholar
• Baker JV, Sharma S, Achhra AC, et al. Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among HIV-Positive participants in the START (strategic timing of antiretroviral treatment) trial. J Am Heart Assoc. 2017;6(5):e004987. doi: 10.1161/jaha.116.004987.
   Web of Science ®Google Scholar
• Hill A, McCann K, Pilkington V, et al. Risks of metabolic syndrome, diabetes, and cardiovascular disease in advance trial. Conference on Retroviruses and Opportunistic Infections (CROI). USA, Boston (Vol. 8, No. 11). 2020.
   Google Scholar
• Quercia R, Roberts J, Martin-Carpenter L, et al. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35(3):211–219. doi: 10.1007/s40261-014-0266-2.
   PubMed Web of Science ®Google Scholar
• Pereira SA, Branco T, Côrte-Real RM, et al. Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients. Br J Clin Pharmacol. 2006;61(5):601–604. doi: 10.1111/j.1365-2125.2006.02619.x.
   PubMed Web of Science ®Google Scholar
• Flint O, Bellamine A, Noor M. Effects of efavirenz on ­lipid metabolism in APOE8*3*Leiden hCETP double-transgenic mice: evidence for antagonism of LXR pathway. Antivir Ther. 2007;12:L5–L6.
   Google Scholar
• Aldredge A, Lahiri CD, Summers NA, et al. Effects of integrase strand-transfer inhibitor use on lipids, glycemic control, and insulin resistance in the women’s interagency HIV study (WIHS). Open Forum Infect Dis. 2019;6(Supplement_2):S38–S38. doi: 10.1093/ofid/ofz359.082.
   Google Scholar
• ULC VH. TRIUMEQ Canada: ViiV Healthcare ULC; 2019. [updated 2019 Jul 4; cited 2021 Nov 20]. Available from: https://viivhealthcare.com/content/dam/cf-viiv/viiv-healthcare/en_GB/medicines/Triumeq_PM_2019-07-04.pdf.
   Google Scholar
• Lamorde M, Atwiine M, Owarwo NC, et al. Dolutegravir-associated hyperglycaemia in patients with HIV. Lancet HIV. 2020;7(7):e461–e2. doi: 10.1016/s2352-3018(20)30042-4.
   PubMed Web of Science ®Google Scholar
• Ngu RC, Choukem S-P, Dimala CA, et al. Prevalence and determinants of selected cardio-metabolic risk factors among people living with HIV/AIDS and receiving care in the south west regional hospitals of Cameroon: a cross-sectional study. BMC Res Notes. 2018;11(1):305. doi: 10.1186/s13104-018-3444-0.
   PubMedGoogle Scholar
• Lo J, Oyee J, Crawford M, et al. Dolutegravir and insulin resistance. Conference on Retroviruses and Opportunistic Infections (CROI). 2019.
   Google Scholar
• Kemal A, Teshome MS, Ahmed M, et al. Dyslipidemia and associated factors among adult patients on antiretroviral therapy in armed force comprehensive and specialized hospital, Addis Ababa, Ethiopia. HIV AIDS. 2020;12:221–231. doi: 10.2147/HIV.S252391.
   Google Scholar
• Ambikairajah A, Walsh E, Cherbuin N. Lipid profile differences during menopause: a review with meta-analysis. Menopause. 2019;26(11):1327–1333. doi: 10.1097/gme.0000000000001403.
   PubMed Web of Science ®Google Scholar
• Anyabolu EN. Dyslipidemia in people living with HIV-AIDS in a tertiary hospital in South-East Nigeria. Pan Afr Med J. 2017;28:204. doi: 10.11604/pamj.2017.28.204.13505.
   PubMedGoogle Scholar
• Ombeni W, Kamuhabwa AR. Lipid profile in HIV-Infected patients using first-line antiretroviral drugs. J Int Assoc Provid AIDS Care. 2016;15(2):164–171. doi: 10.1177/2325957415614642.
   PubMedGoogle Scholar
• Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289(22):2978–2982. doi: 10.1001/jama.289.22.2978.
   PubMed Web of Science ®Google Scholar
• Rasoolinejad M, Najafi E, Hadadi A, et al. Prevalence and associated risk factors of hyperglycemia and diabetes mellitus among HIV positive patients in Tehran, Iran. Infect Disord Drug Targets. 2019;19(3):304–309. doi: 10.2174/1871526518666180723152715.
   PubMedGoogle Scholar
• Arafath S, Campbell T, Yusuff J, et al. Prevalence of and risk factors for prediabetes in patients infected with HIV. Diabetes Spectr. 2018;31(2):139–143. doi: 10.2337/ds17-0009.
   PubMedGoogle Scholar
• Faerch K, Borch-Johnsen K, Holst JJ, et al. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia. 2009;52(9):1714–1723. doi: 10.1007/s00125-009-1443-3.
   PubMed Web of Science ®Google Scholar
• Gupta G, Wadhwa R, Pandey P, et al. Obesity and diabetes: pathophysiology of obesity-induced hyperglycemia and insulin resistance. Pathophysiology of obesity-induced health complications. 2020. p. 81–97.
   Google Scholar
• Muhammad F, Uloko A, Ramalan M, et al. Prevalence of diabetes mellitus among HIV patients in Kano, northwestern Nigeria. Endocrine Abstracts. Bioscientifica. 2015. doi: 10.1530/endoabs.38.P244.
   Google Scholar
• Tiozzo E, Rodriguez A, Konefal J, et al. The relationship between HIV duration, insulin resistance and diabetes risk. Int J Environ Res Public Health. 2021;18(8):3926. doi: 10.3390/ijerph18083926.
   PubMed Web of Science ®Google Scholar
• Hadigan C, Kattakuzhy S. Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus. Endocrinol Metab Clinics North Am. 2014;43(3):685–696. doi: 10.1016/j.ecl.2014.05.003.
   PubMed Web of Science ®Google Scholar